nomination form banner

2020 Winners

We are honored to spotlight the winners for their inspiring work to create a brighter future for cancer patients and their loved ones. Learn more about their work.

C2 Catalyst for Change Award

Lynette Bonar, RN, BSN, MBA, FACHE

CEO, Tuba City Regional Health Care Corporation (TCRHCC)

C2 Catalyst for Care Award

Jill Kincaid

Founder & CEO, Chemo Buddies

C2 Catalyst for Precision Medicine Award

Lincoln D. Nadauld, MD, PhD

Vice President & Chief of Precision Health and Academics Intermountain Healthcare

President’s Award

Richard A. Dean, Ph.D.

Volunteer, Patient and Family Advisory Council, Johns Hopkins Hospital

2020 Finalists

Congratulations to the finalists who have been recognized by their peers for the inspiring work they do each day – all collectively working to make a difference for those living with and affected by cancer.

Our Judges

Meet Our Judges

Finalists and winners in the Catalyst for Change, Catalyst for Care and Catalyst for Precision Medicine categories were selected by an esteemed panel of judges from across the cancer community.

C2 Cancer Community (C2) Awards

holding hands couple
holding hands couple holding hands couple

C2 Cancer Community (C2) Awards

Advancing cancer care requires more than just science. It’s a collective effort driven by passionate individuals and organizations dedicated to making a difference for those living with and affected by cancer.

For patients and their families, the community of healthcare professionals, researchers, caregivers, advocates, educators and others who offer relief in extraordinarily difficult times are worth celebrating. The Awards honor this diverse and indispensable group, the unsung heroes of cancer care.

2019-2020 Categories

Click here to see the Rules and Regulation.

Scientific advancements in cancer care and treatment can save lives, but often ensuring these advancements reach the community-level or more rural areas can be a challenge. Nominees for the C2 Catalyst for Change Award are working to change that.

Nominees for this award drive change at the community-, neighborhood- or hospital-level that results in better cancer care for more people. Maybe a Nominee found a way to get more people screened for cancer at an earlier stage or figured out a creative approach to access new treatments or facilities. Or perhaps the Nominee created a science-based communication, initiative or event that improved access to cancer care and treatment. The C2 Catalyst for Change Award celebrates those who significantly improve access to cancer care for underserved populations.

Award Criteria

  • A Nominee needs to significantly improve the ability of underserved populations to receive high-quality cancer care. Examples include:
    • Improving access to treatment and quality cancer care for patients who previously went without it.
    • Creating more space at a facility that lacked it, facilitating the treatment of more patients.
    • Developing an educational cancer-prevention program in a region with a lack of knowledge.
    • Improving a community’s ability to serve cancer patients through advocacy, government relations or media attention.
  • A Nominee should be able to demonstrate measurable impact, whether as people reached, populations served, procedures increased, screens undertaken, etcetera.
  • Ideally, a Nominee’s process/methodology/approach could be applied in other communities to further expand access to patients in underserved areas.

How a patient feels during treatment and what happens outside the clinic matters just as much as the treatment itself. Nominees for the C2 Catalyst for Care Award work to improve the patient experience.

Nominees may have developed a system where providers go to patients, helped to make hospitals feel like home, or created a transportation service to provide free rides to medical appointments. A nominee might help patients or their families manage challenges beyond medical care, such as finances or quality-of-life issues. This award is all about making a patient’s experience as easy as possible during an extraordinarily difficult time.

Award Criteria

  • A Nominee needs to significantly enhance the experience of cancer care for patients at some stage in their cancer treatment, from diagnosis and beyond. Examples include:
    • Developing improved hospital facilities or quality-of-care programs, such as new wards, new food menus or transportation services.
    • Advocating for improved quality-of-life services.
    • Creating easy-to-use digital adherence tools.
    • Improving the experience of patient families, helping them navigate a very difficult time.
  • A winner should be able to demonstrate measurable impact, whether as patients reached, programs started, meals prepared, rides given, etcetera.
  • Ideally, the tools or techniques required to implement the winner’s activity or program should be something that could apply to cancer-care across the country.

Many of the most promising advances in cancer care come from the area of precision medicine, which uses specific characteristics of a patient’s cancer to inform doctors what the best treatment may be for that individual. The Nominee of the C2 Catalyst for Precision Medicine Award is expanding the boundaries for how to personalize care for each patient, bringing new, more individualized tests and treatments to patients and improving health outcomes in the process.

A Nominee might have pioneered new research to help oncologists understand the genetics of a patient’s cancer differently and thereby provide better treatment options. Or a Nominee may have created new protocols to identify which specific patients may benefit from a specific treatment protocol. This award celebrates those who enhance the ability to provide the right treatment for the right patient at the right time.

Award Criteria

  • A Nominee needs to significantly improve personalized treatments for cancer patients, giving them new options. Examples include:
    • Developing a new kind of precision-oncology method that leads to measurable improvements in health outcomes.
    • Developing tools to help identify patients who may benefit from a new precision-oncology approach.
    • Leading research that identifies new, more personalized options for cancer treatment.
    • Spearheading a new policy to enhance testing or screening for a specific cancer mutation.
  • A winner should be able to demonstrate measurable impact, such as patients treated, programs started, etcetera.
  • Ideally, the tools or techniques required to implement the winner’s activity or program should be something that could apply across the country.

Cancer does not have any fixed rules, nor does the President’s Award, save one: The winner must make a tangible and inspiring difference in the lives of patients or their loved ones. A Nominee may have started a 5K race to raise enough money
to pay a certain patient’s treatment. A Nominee may have built a cancer survivor support group or online forum. A Nominee might even have changed a loved one’s life by becoming an advocate or caregiver or a volunteer hospice worker.  The President’s Award is selected by an AstraZeneca executive for making a meaningful impact on the lives of cancer patients.

Award Criteria

  • The winner’s contributions benefited the cancer community in an inspirational way that lies outside of the criteria for the other C2 Awards.
  • This winner should show an unexpected way to contribute to the cancer community and demonstrate how they have improved the life of even one cancer patient.

Our Partner

The program is a partnership between AstraZeneca and Scientific American Custom Media and nominees will be selected by a broad group of experts drawn from our community.

Scientific American has been bringing its global audience unique insights into science, technology and medicine for more than 170 years. The C2 Awards are a partnership with Scientific American Custom Media, working with a group patient advocates, caregivers, healthcare providers, leaders in industry and members of government agencies to select Nominees.